Concepedia

Chenglong Yue

CY

Statistics

Publications

9

Citations

372

H-Index

9

Active since

2016

Affiliations

Xuzhou Medical College(Current)

Xuzhou Children Hospital

Second People’s Hospital of Huai’an

Chenglong Yue is an author at Xuzhou Medical College specializing in molecular oncology, medicine, and oncology.

Publications per year

2016–2024

9

Publications

9

The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Xuejiao Liu, Xiangyu Chen, Lin Shi et al. · Journal of Experimental & Clinical Cancer Research · 2019 · 114 citations · Full text

, , +17

CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways

Xuejiao Liu, Yulong Chong, Yiming Tu et al. · Journal of Hematology & Oncology · 2016 · 80 citations · Full text

, , +17

High expression of Bruton’s tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma

Chenglong Yue, Mingshan Niu, Qian Qian Shan et al. · Journal of Experimental & Clinical Cancer Research · 2017 · 49 citations · Full text

, , +17

MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR‐induced NF‐κB activation

Xuejiao Liu, Chenglong Yue, Lin Shi et al. · Journal of Cellular and Molecular Medicine · 2020 · 32 citations · Full text

, , +17

Smoothened is a poor prognosis factor and a potential therapeutic target in glioma

Yiming Tu, Mingshan Niu, Peng Xie et al. · Scientific Reports · 2017 · 26 citations · Full text

, , +17

1–5 of 9